デフォルト表紙
市場調査レポート
商品コード
922031

世界の多形性膠芽腫( 膠芽腫、GBM)治療市場:成長、動向、および予測

Glioblastoma Multiforme Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 112 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.10円
世界の多形性膠芽腫( 膠芽腫、GBM)治療市場:成長、動向、および予測
出版日: 2020年06月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 112 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートは世界の多形性膠芽腫( 膠芽腫、GBM)治療市場について調査しており、市場機会や動向、成長および阻害要因、治療・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場成長要因
    • 脳障害の有病率増加
    • 主要企業からの強力な研究開発イニシアチブ
    • 高齢化人口の増加
  • 市場阻害要因
    • 償還問題と厳格な規制ガイドライン
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • 治療別
    • 化学療法
    • 放射線療法
    • その他
  • エンドユーザー別
    • 病院/診療所
    • 外来手術センター
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Arbor Pharmaceuticals, LLC
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Merck & Co. Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.

第7章 市場機会および今後の動向

目次
Product Code: 67539

A brain tumor occurs when abnormal cells form as well as grow within a brain. Factors such as the increasing burden of brain disorders, strong R&D initiatives from key players and rising geriatric population are boosting the growth of the glioblastoma multiforme treatment market. As per the estimates of Globocan 2018, the number of new cases of brain cancer across the world was 296,851 in 2018. This leads to increased care providers shifting to the mainstream treatment associated with the glioblastoma treatment. Hence, the growing focus toward the development of better treatment options invites more cancer chemotherapy based companies to generate innovative drugs as well as explore different geographic regions to grow the sales of chemotherapy and radiation therapy products thus fueling the growth of glioblastoma multiforme treatment market.

However, reimbursement issues and stringent regulatory guidelines and high cost and side effects associated with therapies are expected to restrain the growth of the global market in the forecast period.

Key Market Trends

Chemotherapy Segment is Expected to Dominate the Market

Based on treatment, the market is segmented into chemotherapy, radiation therapy, and others. The chemotherapy segment is expected to dominate the market. The key factor contributing to the growth of the segment is the rising number of brain and other nervous system cancers. Many companies are focusing on developing generic products for the treatment of neurological diseases like brain stroke; as well as glioblastoma in order to maintain their competitive advantage and penetrate new regional markets across the developed and emerging markets. In addition, the pipeline of glioblastoma multiforme is rich with the number of drugs that are expected to receive FDA approval steadily over the period. Also, an increase in funding for companies involved in the research related to glioblastoma is expected to boost the interest of venture partner companies, investors and new mergers as well as acquisition-related to this segment of the studied market.

North America leads the Glioblastoma Multiforme Treatment Market

North America leads the glioblastoma multiforme treatment market, owing to rise in funding initiatives and awareness among patients, followed by Europe. According to the American Society of Clinical Oncology (ASCO), in 2019, it was expected that an estimated 23,820 adults (13,410 men and 10,410 women) in the United States will be diagnosed with primary cancerous tumors of the brain and spinal cord. Brain tumors account for 85% to 90% of all primary CNS tumors. However, Asia Pacific is expected to grow at a faster rate due to the increasing awareness regarding advanced treatment options, and the presence of emerging economies in this region.

Competitive Landscape

The leading players in the global glioblastoma multiforme treatment market are - Arbor Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sun Pharmaceutical and Teva Pharmaceutical Industries Ltd.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Brain Disorders
    • 4.2.2 Strong R&D Initiatives from Key Players
    • 4.2.3 Increasing Aging Population
  • 4.3 Market Restraints
    • 4.3.1 Reimbursement Issues and Stringent Regulatory Guidelines
    • 4.3.2 High Cost and Side Effects Associated with Therapies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Treatment
    • 5.1.1 Chemotherapy
      • 5.1.1.1 Temozolomide
      • 5.1.1.2 Bevacizumab
      • 5.1.1.3 Carmustine
      • 5.1.1.4 Other Types of Chemotherapy
    • 5.1.2 Radiation Therapy
    • 5.1.3 Other Treatments
  • 5.2 By End User
    • 5.2.1 Hospitals/Clinics
    • 5.2.2 Ambulatory Surgical Centers
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Arbor Pharmaceuticals, LLC
    • 6.1.2 Bristol-Myers Squibb Company
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 F. Hoffmann-La Roche Ltd
    • 6.1.5 Merck & Co. Inc.
    • 6.1.6 Sun Pharmaceutical Industries Ltd.
    • 6.1.7 Teva Pharmaceutical Industries Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS